In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for TRELEGY® ELLIPTA® and earlier-stage programs partnered with Theravance Biopharma, Inc.

In the United States, BREO ELLIPTA is not proposed for the relief of acute bronchospasm or for the treatment of asthma. GSK and Theravance are reviewing the strategy for a future US filing for asthma.

The daily inhaled corticosteroid is approved for asthma maintenance among patients 12 and up, and joins the new respiratory series which includes Breo Ellipta (fluticasone furoate and vilanterol ...

British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines ...

Do not use Breo Ellipta for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids. Breo Ellipta is NOT indicated for the relief of acute bronchospasm.

Chalk up another real-world trial win for GlaxoSmithKline. A year after showing the company’s Breo Ellipta could beat out go-to COPD treatments at cutting down exacerbations, new data says the ...

Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more ...

Trelegy Ellipta was originally approved for use in the US in September 2017 for the long-term, once-daily, maintenance treatment of COPD patients who are receiving Breo and require additional ...

* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma * Today's filing is based upon data generated from comprehensive clinical ...

Breo, administered by the new Ellipta dry powder inhaler, is indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis ...

GlaxoSmithKline (GSK.L) notched up a second win for its pioneering "real world" approach to testing new drugs on Friday as its inhaled medicine Breo proved significantly better than standard care ...

Trelegy Ellipta was approved in the European Union in November 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) who are not adequately treated by an ICS/LABA ...